Tags

Type your tag names separated by a space and hit enter

Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
EuroIntervention 2010; 5(8):962-7E

Abstract

AIMS

Assessment of health related quality-of-life (HRQL) has become increasingly important as not only the clinician's view of the technical success, but also the patient's perception is being measured. We evaluated the HRQL following sirolimus-eluting coronary stent (SES) (CYPHER(R); Cordis, Johnson & Johnson, Warren, NJ, USA) implantation in patients with multivessel disease, comparing the outcomes with the historical surgical and bare metal stent (BMS) arms of the ARTS-I study.

METHODS AND RESULTS

The HRQL outcomes were compared to the outcome of the historical cohorts of the randomised ARTS-I trial using the same inclusion and exclusion criteria. HRQL was evaluated at baseline, at one month and at 6, 12 and 36 months after revascularisation using the SF-36 in patients treated with SES (n=585), BMS (n=483) or coronary artery bypass graft (CABG) (n=492). The HRQL compliance rates varied from 100% at baseline to 92% at 36 months. Both stenting and CABG resulted in significant improvement of HRQL and anginal status. There was a trend towards better HRQL after CABG than BMS beyond six months. Already from the first month up to three years, SES patients had, on average, 10% significantly better HRQL than BMS patients on the HRQL subscales physical functioning, role physical functioning, role emotional functioning and mental health (p<0.01) and a trend towards better HRQL in the other subscales. Up to 12 months, the HRQL was better after SES than CABG and was identical thereafter. At all time points, angina was more prevalent in the BMS group than in both the SES and CABG groups, in which the incidence of angina was similar. At three years, 10% of the SES patients suffered from angina, 13% of the CABG patients and 20% of the BMS patients.

CONCLUSIONS

Both stenting and CABG resulted in a significant improvement in HRQL and angina. Along with a substantial reduction of restenosis, HRQL after SES was significantly improved as compared with BMS, and was similar to CABG.

Authors+Show Affiliations

Erasmus Medical Center, Rotterdam, The Netherlands. r.vandomburg@erasmusmc.nl <r.vandomburg@erasmusmc.nl>No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

20542782

Citation

van Domburg, Ron T., et al. "Short- and Long-term Health Related Quality-of-life and Anginal Status of the Arterial Revascularisation Therapies Study Part II, ARTS-II; Sirolimus-eluting Stents for the Treatment of Patients With Multivessel Coronary Artery Disease." EuroIntervention : Journal of EuroPCR in Collaboration With the Working Group On Interventional Cardiology of the European Society of Cardiology, vol. 5, no. 8, 2010, pp. 962-7.
van Domburg RT, Daemen J, Morice MC, et al. Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention. 2010;5(8):962-7.
van Domburg, R. T., Daemen, J., Morice, M. C., de Bruyne, B., Colombo, A., Macaya, C., ... Serruys, P. W. (2010). Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention : Journal of EuroPCR in Collaboration With the Working Group On Interventional Cardiology of the European Society of Cardiology, 5(8), pp. 962-7. doi:10.4244/.
van Domburg RT, et al. Short- and Long-term Health Related Quality-of-life and Anginal Status of the Arterial Revascularisation Therapies Study Part II, ARTS-II; Sirolimus-eluting Stents for the Treatment of Patients With Multivessel Coronary Artery Disease. EuroIntervention. 2010;5(8):962-7. PubMed PMID: 20542782.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. AU - van Domburg,Ron T, AU - Daemen,Joost, AU - Morice,Marie-Claude, AU - de Bruyne,Bernard, AU - Colombo,Antonio, AU - Macaya,Carlos, AU - Richardt,Gert, AU - Fajadet,Jean, AU - Hamm,Christian, AU - van Es,Gerrit-Anne, AU - Wittebols,Kristel, AU - Macours,Nathalie, AU - Stoll,Hans Peter, AU - Serruys,Patrick W, PY - 2010/6/15/entrez PY - 2010/6/15/pubmed PY - 2010/9/29/medline SP - 962 EP - 7 JF - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JO - EuroIntervention VL - 5 IS - 8 N2 - AIMS: Assessment of health related quality-of-life (HRQL) has become increasingly important as not only the clinician's view of the technical success, but also the patient's perception is being measured. We evaluated the HRQL following sirolimus-eluting coronary stent (SES) (CYPHER(R); Cordis, Johnson & Johnson, Warren, NJ, USA) implantation in patients with multivessel disease, comparing the outcomes with the historical surgical and bare metal stent (BMS) arms of the ARTS-I study. METHODS AND RESULTS: The HRQL outcomes were compared to the outcome of the historical cohorts of the randomised ARTS-I trial using the same inclusion and exclusion criteria. HRQL was evaluated at baseline, at one month and at 6, 12 and 36 months after revascularisation using the SF-36 in patients treated with SES (n=585), BMS (n=483) or coronary artery bypass graft (CABG) (n=492). The HRQL compliance rates varied from 100% at baseline to 92% at 36 months. Both stenting and CABG resulted in significant improvement of HRQL and anginal status. There was a trend towards better HRQL after CABG than BMS beyond six months. Already from the first month up to three years, SES patients had, on average, 10% significantly better HRQL than BMS patients on the HRQL subscales physical functioning, role physical functioning, role emotional functioning and mental health (p<0.01) and a trend towards better HRQL in the other subscales. Up to 12 months, the HRQL was better after SES than CABG and was identical thereafter. At all time points, angina was more prevalent in the BMS group than in both the SES and CABG groups, in which the incidence of angina was similar. At three years, 10% of the SES patients suffered from angina, 13% of the CABG patients and 20% of the BMS patients. CONCLUSIONS: Both stenting and CABG resulted in a significant improvement in HRQL and angina. Along with a substantial reduction of restenosis, HRQL after SES was significantly improved as compared with BMS, and was similar to CABG. SN - 1969-6213 UR - https://www.unboundmedicine.com/medline/citation/20542782/Short__and_long_term_health_related_quality_of_life_and_anginal_status_of_the_Arterial_Revascularisation_Therapies_Study_part_II_ARTS_II L2 - https://medlineplus.gov/coronaryarterybypasssurgery.html DB - PRIME DP - Unbound Medicine ER -